Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

Osteoporosis International

Volumn 26, Issue 10, 2015, Pages 2479-2489

  Hadji, P ^a   Papaioannou, N ^b   Gielen, E ^c   Feudjo Tepie, M ^d   Zhang, E ^d   Frieling, I ^e   Geusens, P ^f,g   Makras, P ^h   Resch, H ⁱ   Moller G ^j   Kalouche Khalil, L ^k   Fahrleitner Pammer, A ^l  

^a KRANKENHAUS NORDWEST   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d AMGEN LTD   (United Kingdom)

^e Osteoporosis Center   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HASSELT UNIVERSITY   (Belgium)

^h IASO GENERAL HOSPITAL   (Greece)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j Practice for Preventive and Regenerative Medicine   (Germany)

^k AMGEN INC   (United States)

^l MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

Adherence; Compliance; Denosumab; Non interventional study; Osteoporosis; Persistence

Indexed keywords

DENOSUMAB; BONE DENSITY CONSERVATION AGENT;

AGED; ARTHRALGIA; ARTICLE; AUSTRIA; BACKACHE; BELGIUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FEMUR NECK; FRACTURE REDUCTION; GERMANY; GREECE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; CLINICAL TRIAL; COMORBIDITY; DRUG ADMINISTRATION; EUROPE; MEDICATION COMPLIANCE; MEDICINE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DENOSUMAB; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MEDICATION ADHERENCE; MEDICINE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PROSPECTIVE STUDIES;

EID: 84942366033     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3164-4     Document Type: Article

References (44)

1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47
2. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231
3. Hoer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Haussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25–30
4. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928
5. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13
6. Lakatos P, Tóth E, Lang Z, Psachoulia E, Intorcia M (2013) Compliance protects against fracture in women with postmenopausal osteoporosis in Hungary. Value Health 16:A567
7. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757–1764
8. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22:1537–1546
9. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018
10. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570–575
11. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310
12. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M et al (2004) Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 22:462–468
13. Lee YH, Song GG (2011) Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340–347
14. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460
15. Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A (2014) The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int 25:339–347
16. Hadji PKS, Häussler B, Kless T, Linder R, Rowinski-Jablokow M, Verheyen F, Gothe H (2013) The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 51:868–872
17. Lakatos P, Tóth E, Cina Z, Lang Z, Psachoulia E, Intorcia M (2013) Persistence & compliance to treatment for osteoporosis in postmenopausal women in Hungary: a retrospective cohort study. Value Health 16:A567–A568
18. Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, Moericke R, Kann PH (2012) Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int 23:2043–2051
19. Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741–753
20. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342
21. Amgen (2014) Prolia® EU Summary of Product Characteristics [Available at: https://www.medicinesorguk/ema/medicine/23127]. Accessed November 2014
22. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161
23. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81
24. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
25. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311–1317
26. Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10:348–354
27. Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I et al (2014) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. doi:10.1007/s00198-014-2871-6
28. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157
29. Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M et al (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47:131–139
30. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831
31. Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2012) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24:209–217
32. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501
33. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396
34. Dachverband Osteologie (2011) DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20:55–74
35. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57
36. Makras P, Vaiopoulos G, Lyritis GP (2012) 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38–42
37. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper J, Stenmark EV, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8:136
38. ISPOR (2008) ISPOR global health care systems road map: Greece [http://www.ispor.org/htaroadmaps/Greece.asp]. Accessed March 2015
39. Institut national d’assurance maladie-invalidité (2014) Liste des spécialités pharmaceutiques remboursables: les catégories de remboursement [http://www.inami.fgov.be/fr/themes/cout-remboursement/par-mutualite/medicament-produits-sante/remboursement/specialites/Pages/liste-specialites-pharmaceutiques-remboursables-categories-remboursement.aspx#.VRExb8JybGg]. Accessed March 2015
40. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951
41. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216
42. Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905
43. Karlsson L, Lundkvist J, Intorcia M, Psachoulia E, Strom O (2013) Treatment persistence in Swedish women initiating denosumab treatment for postmenopausal osteoporosis. Value Health 16:A567
44. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326